Joaquin Seras Franzoso I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB). Institucions de les que formen part Investigador/a principal Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Joaquin Seras Franzoso LinkedIn Twitter Orcid Institucions de les que formen part Investigador/a principal Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia Vall Hebron Institut de Recerca I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).
I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles. I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy. I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.
Projectes Nanoclustered Affimers for Targeted KRAS Ablation in Pancreatic Ductal Adenocarcinoma IP: Joaquin Seras Franzoso Col·laboradors: Diana Fernandes de Rafael Entitat finançadora: Asociación Cáncer de Páncreas Finançament: 50000 Referència: ACANPAN/PROJECTES/2023/SERAS Durada: 05/12/2023 - 04/12/2025 Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT) IP: - Col·laboradors: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Diana Fernandes de Rafael, Maria Francesca Cortese , Sandra Mancilla Zamora Entitat finançadora: Agència Gestió Ajuts Universitaris i de Recerca Finançament: 60000 Referència: 2021 SGR 01173 Durada: 01/01/2022 - 30/06/2025 Impacto y valor pronóstico de vesículas extracelulares tumorales provenientes de células madre cancerígenas en tumores de mama triple negativo. IP: Joaquin Seras Franzoso Col·laboradors: Laura García Latorre, Diego Baranda Martínez-Abasca, Esther Zamora Adelantado, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Belen Garcia Prats Entitat finançadora: Instituto de Salud Carlos III Finançament: 99220 Referència: PI22/01301 Durada: 01/01/2023 - 31/12/2026 MIMIC-KeY - A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES. IP: Simon Schwartz Navarro Col·laboradors: Joaquin Seras Franzoso, Julia German Cortes, Zamira Vanessa Diaz Riascos Entitat finançadora: EUROPEAN COMMISSION Finançament: 457250 Referència: MIMIC-KEY_H2020-FETPROACT-2020 Durada: 01/06/2021 - 30/11/2025 Paginació Primera pàgina « Pàgina anterior ‹ Page 1 Pàgina actual 2 Page 3 Page 4 Pàgina següent › Última pàgina »
